Navigation Links
Bioponic Phytoceuticals Announces Curecumin(TM) May Lower Heart Failure Risk
Date:4/16/2008

KULA, Maui, April 16 /PRNewswire/ -- Bioponic Phytoceuticals, Inc. (OTC: BPYT) ("Bioponic" or "the Company") today announced that curcumin, the key ingredient in the Company's Curecumin(TM) product (a Bioresonant Phytotherapeutic(R) form of curcumin in a liquid delivery system) may be an important treatment for lowering heart failure risk. Bioponic currently sells Curecumin in a 1 oz. oral spray and a 1 oz. nasal pump spray bottle. Research findings and product information on Curecumin's many therapeutic qualities can be found at http://www.curecumin.com.

In a recent study entitled, "Curcumin prevents and reverses murine cardiac hypertrophy," published in the February 2008 edition of the Journal of Clinical Investigation, researchers found that when the herb was given orally to a variety of mouse models with enlarged hearts (hypertrophy), it can prevent and reverse hypertrophy, restore heart function and reduce scar formation.

"Whether you are young or old; male or female; the larger your heart is, the higher your risk is for developing heart attacks or heart failure in the future," explains Dr. Liu, a cardiologist in the Peter Munk Cardiac Centre at the Canadian Institutes of Health Research - Institute of Circulatory and Respiratory Health. If clinical trials of curcumin support initial findings of heart enlargement prevention, it may offer hope for millions of patients with heart enlargement. Dr. Liu, who holds the Heart and Stroke Foundation's Polo Chair Professor in Medicine and Physiology at the University of Toronto, says that curcumin may be a safe and effective means of preventing heart failure in the future. This study was funded by the Heart and Stroke Foundation and the Canadian Institutes of Health Research.

"Curcumin has been the subject of extensive research over the past few years, and has been shown to protect the liver, inhibit tumors, reduce inflammation and prevent the formation of the amyloid beta plaques which cause Alzheimer's Disease. We are encouraged by yet another study that suggests the versatile curcumin may lower heart failure risk," said Steven M. Schorr, Chairman and CEO of Bioponic. "More than 5 million Americans are living with heart failure, and 550,000 new cases are diagnosed each year, according to the American Heart Association. The potential that our Curecumin(TM) product (http://www.curecumin.com) could provide a viable treatment strategy for those at risk for heart failure is very exciting. If proven effective, we may have an efficacious, cost effective, natural treatment for heart failure sufferers."

About Bioponic Phytoceuticals

Bioponic Phytoceuticals is engaged in the development, production and distribution of Bioresonant Phytotherapeutic(TM) products. The Company has developed several branded product lines (including the nasal spray: Flight Spray(R) (http://www.flightspray.com) and the skincare product Hawaiian Healing Mist(TM)). Bioponic is focused on the production of natural products that are used to promote health and well-being. Visit http://www.bioponic.com.

All statements other than statements of historical fact included in this press release are "forward-looking statements" within the meaning of federal securities laws. Such forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the Company's control.


'/>"/>
SOURCE Bioponic Phytoceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioponic Phytoceuticals Announces Master Distributorship With Natures Best Covering 1,000 West Coast Retailers
2. Bioponic Phytoceuticals Introduces All Natural Baby Product Suite Gentle Mother
3. Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations
4. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
5. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
6. Dubai Cares Announces 12 Country Plan to Educate and Empower Children in Developing Nations
7. ECO2 Plastics, Inc. Reports 2007 Year End Financial Results, Announces FDA Filing and Provides Outlook for 2008
8. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
9. The Pancreatic Cancer Action Network Announces Its 2008 Research Grant Awards Totaling Over $1 Million in New Research Funding
10. Parallel Software Announces Integrated Credit Card Processing for MacPractice MD, DDS, DC and 20/20
11. HealthSouth Announces Date of 2008 First Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused on ... efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, Jr. ... honored to team up with Upstage Lung Cancer in order to make major strides ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... Dec. 8, 2016  Pennsylvania Physician General Dr. ... and Alcohol Programs Gary Tennis released ... known as benzodiazepines, developed with the help of ... medications that are frequently prescribed for anxiety or ... used with opioid pain medications, benzodiazepines pose a ...
Breaking Medicine Technology: